Expert consensus on the off-label use of drugs for pediatric rare diseases in China (2025 edition) Authors: Xiaolan Mo, Houliang Deng, Jinlian Yang, Jiale Li, Shan Ouyang, Feng Chen, Yanqin Cui, Xia Gao, Hua Jiang, Xiaojing Li, Li Liu, Jie Liu, Lin Qiu, Xiaoming Rong, Zhe Wen, Jiayi Wang, Ping Zeng, Wen Zhang, Xiaopeng Zhao, Juan Zhou, Jie Chen, Pan Chen, Wenying Chen, Zebin Chen, Rui Fang, Xiaomei Fan, Yuntao Jia, Zhiling Li, Xuejuan Li, Xiaoyan Li, Yunzhu Lin, Maochang Liu, Haiyan Mai, Jing Miao, Xiaoling Wang, Yong Wang, Jinghao Wang, Li Wei, Junyan Wu, Shanshan Yu Published: 2025 ABSTRACT BackgroundThe package insert is a key reference and legal basis for clinical medication. However, in the field of rare diseases, advances in diagnosis and treatment often outpace updates to drug labels, resulting in widespread off-label drug use—a practice that is particularly common and often unavoidable in pediatric populations. Inappropriate off-label use, however, carries significant clinical and safety risks.MethodsUnder the guidance of the Rare Disease Expert Committee of the Guangdong Pharmaceutical Association, a multidisciplinary panel of experts from clinical medicine, pharmacy, and related specialties developed the “Expert consensus on the off-label use of drugs for pediatric rare diseases in China (2025 edition)”. The consensus integrates available evidence, clinical experience, evidence quality, and medication safety profiles, and was finalized after several rounds of rigorous iterative review.ResultsThe consensus presents 73 recommendations on off-label drug use across 21 rare diseases, organized in a tabular format for clarity and ease of reference.ConclusionsThis consensus aims to standardize the management of off-label drug use in pediatric rare diseases. It supports medical institutions in developing off-label drug formularies, promotes rational drug use, and helps address the diagnostic and therapeutic needs of pediatric rare disease patients. Furthermore, it contributes to the establishment of a structured evaluation and management framework for off-label drug use in this clinical context. Highlight box Key recommendations • This consensus provides evidence-based support for the treatment of pediatric rare diseases included in China’s First and Second Batches of the Rare Disease Catalog, and offers guidance on the management of off-label drug use. What was recommended and what is new? • Currently, there is a lack of comprehensive guidelines or expert consensus in China specifically addressing off-label drug use in pediatric rare diseases. • The consensus includes a total of 73 recommendations addressing off-label drug use across 21 pediatric rare diseases. What is the implication, and what should change now? • Off-label drug use should be reserved for circumstances where on-label alternatives are unavailable or ineffective. When clinically necessary, physicians must conduct a thorough benefit-risk analysis and strictly adhere to institutional protocols governing such practices. Introduction The package inserts, serving as a critical reference for clinical medication, constitute the legal standard guiding physicians and pharmacists in the rational use of pharmaceuticals. Off-label drug use refers to the administration of medications beyond the scope defined by the drug label and instruction manual, as approved by national regulatory authorities, encompassing but not limited to unapproved indication, dosage, dosing frequency, the course of treatment or population (1). The rapid advancement of diagnostic and therapeutic technologies for rare diseases, coupled with the relatively delayed updates to package inserts, has made off-label drug use a prevalent practice in clinical settings (2). In pediatric rare diseases, off-label drug use is often unavoidable due to systemic challenges: (I) limited treatment options: low disease prevalence and insufficient research and development incentives result in a paucity of pediatric-specific clinical data and approved drugs for children; (II) data scarcity: ethical restrictions on pediatric trials necessitate heavy reliance on extrapolated adult data; (III) prolonged drug development: complex pathogenesis and children’s distinct physiology extend drug development cycles, causing regulatory delays; (IV) high clinical urgency: significant risks of disability and mortality compel the use of therapies that, although unapproved, may offer potential therapeutic benefits. The Chinese “Law on Doctors” provides a legal framework and safeguards for off-label drug use (3). However, the inappropriate use of medications off-label poses substantial clinical and safety risks (4). To date, no comprehensive guidelines or expert consensus exist regarding off-label drug use for pediatric rare diseases in China. To address this gap, and to promote standardized and rational medication practices, the Rare Disease Expert Committee of the Guangdong Pharmaceutical Association has developed the “Expert consensus on the off-label use of drugs for pediatric rare diseases in China (2025 edition)” (hereafter referred to as the “Consensus”). This document aims to provide evidence-based medical guidance for the off-label use of commonly prescribed drugs in pediatric rare disease treatment, standardize off-label drug use practices, and enhance pharmaceutical monitoring pharmacovigilance in this vulnerable population. Methods The consensus scope and target population This consensus is applicable to healthcare institutions across all levels for the treatment of pediatric rare diseases. The target patient population encompasses individuals under younger than 18 years diagnosed with conditions listed in the First or Second Batch of China’s Rare Disease Catalog (5,6). The rare diseases and off-label drugs covered in this consensus are listed in Table S1. The target healthcare professionals for this consensus include physicians, pharmacists, nurses, and policymakers engaged in managing rare diseases. The methodology of the consensus development Using a nominal group technique, an experienced moderator guided 48 domain experts in structured discussions on the off - label use of drugs for pediatric rare diseases. The consensus development and reporting processes were conducted in strict accordance with established guidelines, including the World Health Organization (WHO) Handbook for Guideline Development (2nd edition, 2014) (7), the Reporting Items for Practice Guidelines in Healthcare (RIGHT) statement (8), and the evidence-based pharmaceutical evaluation methods for off-label drug use (9). Potential conflicts of interest and disclosure management were addressed following the International Committee of Medical Journal Editors’ Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. Consensus panels The group members comprised experts from the following disciplines: clinical physician, pharmacist, and pharmaceutical administration. The composition and positions of the panel members are shown in Table S2. Evidence retrieval and data extraction The “Consensus” document systematically compiles drugs frequently used off-label for the treatment of pediatric rare diseases. The document is presented in a tabular format to enhance clarity and is organized according to therapeutic applications. The selection criteria for these drugs are derived from the “2024 Guangdong Pharmaceutical Association Off-Label Drug Use Directory” (10), with adjustments for the unique aspects of rare disease medications: Included in the package inserts of the United States, European Medicines Agency (EMA), or the United Kingdom; Included in the package inserts of the United States, European Medicines Agency (EMA), or the United Kingdom; Listed in the “Chinese Pharmacopoeia Clinical Medication Instructions”, “Clinical Diagnosis and Treatment Guidelines” (published by the Chinese Medical Association and People’s Medical Publishing House), or included in official documents issued by the National Medical Products Administration or the National Health Commission of China; Listed in the “Chinese Pharmacopoeia Clinical Medication Instructions”, “Clinical Diagnosis and Treatment Guidelines” (published by the Chinese Medical Association and People’s Medical Publishing House), or included in official documents issued by the National Medical Products Administration or the National Health Commission of China; Included in leading international and Chinese guidelines or consensus documents; Included in leading international and Chinese guidelines or consensus documents; Rated by Micromedex® with an efficacy rating and recommendation level IIb or evidence level C or higher; Rated by Micromedex® with an efficacy rating and recommendation level IIb or evidence level C or higher; Supported by published randomized controlled trials in first-quartile (Q1) Science Citation Index (SCI) journals within the relevant field; for anti-tumor agents, support should be provided by observational studies or confirmatory clinical trials demonstrating clinical benefits, published in Q1 SCI journals. Supported by published randomized controlled trials in first-quartile (Q1) Science Citation Index (SCI) journals within the relevant field; for anti-tumor agents, support should be provided by observational studies or confirmatory clinical trials demonstrating clinical benefits, published in Q1 SCI journals. The extraction procedure was independently performed by two investigators to ensure methodological rigor. Following the completion of the extraction process, the obtained results were systematically cross-verified. In instances where discrepancies were identified during the extraction phase, these were thoroughly deliberated upon, and a consensus was achieved either through mutual agreement or by arbitration conducted by a third independent researcher. The formulation and revision of consensus The writing committee developed evidence-based recommendations through a systematic review of the current literature. Following extensive deliberations among subject matter experts, which involved a rigorous evaluation of the available evidence base and its alignment with current clinical practices, the initial draft of the expert consensus statement was systematically developed. Subsequently, guideline committee members critically evaluated and provided substantive feedback on the consensus, culminating in the establishment of a finalized consensus. The “Consensus” is structured in a tabular format to enhance clarity and conciseness. Each entry in the consensus table includes the following elements: “Generic Name” (drug’s official generic designation), “Dosage Form”, “Off-label content” (type of off-label use) including “Indication” and “Population”, “Specific usage and dosage” (outlining the dosage and administration details for off-label use), “Evidence and References” (citations that support off-label use), and “Evidence Level” (Micromedex). Results Off-label drug use for pediatric Alport syndrome (AS) treatment AS is a syndrome characterized by clinical manifestations of hematuria, proteinuria, and progressive renal function decline, and some patients also show extrarenal symptoms such as sensorineural hearing loss and ocular lesions (11). AS has been reported to affect around one in 5,000 individuals and accounts for 0.5% of newly diagnosed end-stage renal disease cases among adults and 12.9% among children (12,13). There is currently no radical therapy for AS. The treatment with renin-angiotensin-aldosterone system (RAAS) blockers, including angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB) and aldosterone antagonists, is recommended to delay the progression of renal failure (14). There is a randomized, placebo-controlled study (phase III) in children with AS, which shows that ramipril (an ACEi) is safe and suggests a significant reduction in the risk of disease progression when started early (15). A recent data from Huang et al. confirms that early initiation of RAAS blockade in pediatric AS is linked to slower progression of kidney disease (16). It is recommended that male patients with X-linked AS, patients with autosomal recessive AS, and patients with digenic AS who are older than 12 months should initiate the treatment with RAAS blockers upon diagnosis (17). For female patients with X-linked AS and patients with autosomal dominant AS who are over 12 months old, it is recommended that they start the treatment with RAAS blockers when trace albuminuria is repeatedly detected, if infection has been excluded (17). Table 1 presents the expert consensus on the off-label use of drugs to treat pediatric AS. Table 1Off-label drug usage catalog for treating pediatric ASGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageRamiprilTabletASChildren >12 monthsOral administration, starting with a dose of 1 mg/(m2·d), gradually increasing to 6 mg/(m2·d) or the maximum tolerated dose (not exceeding 10 mg/d, and for patients with impaired renal function, not exceeding 5 mg/d), over a period of 3 to 4 months(I) Expert consensus on the diagnosis and treatment of Alport syndrome (version 2023) (17). (II) Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020 (14)Not listed in MicromedexLisinoprilTablet/capsuleASChildren >12 monthsAdministered orally, the initial dose is 0.2 mg/(kg·d) (max 10 mg/d), gradually increasing to 0.6 mg/(kg·d) (not exceeding 40 mg/d) or until the maximum tolerated dose is reached, over a period of 3 to 4 months(I) Expert consensus on the diagnosis and treatment of Alport syndrome (version 2023) (17). (II) Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020 (14)Not listed in MicromedexEnalaprilTablet/capsule/oral solutionASChildren >12 monthsOral administration, starting dose of 2–4 mg/(m2·d), gradually increasing the dose until the target urine protein-to-creatinine ratio is achieved or drug intolerance occurs [not exceeding 12 mg/(m2·d)](I) Expert consensus on the diagnosis and treatment of Alport syndrome (version 2023) (17). (II) Recommendations for the diagnosis and treatment of Alport syndrome (18)Effectiveness Class IIa, Recommendation Class IIa, Evidence Category BLosartanTablet/capsuleAS–Oral administration, starting dose of 12.5 mg/(m2·d), doubling every 3 months until reaching 50 mg/(m2·d) or the maximum tolerated dose by the patient (not exceeding 100 mg/d)(I) Expert consensus on the diagnosis and treatment of Alport syndrome (version 2023) (17). (II) Recommendations for the diagnosis and treatment of Alport syndrome (18)Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BIrbesartanTablet/capsuleASChildren >12 monthsOral administration, starting dose of 37.5 mg/(m2·d), gradually increasing the dose until the target urine protein-to-creatinine ratio is achieved or drug intolerance occurs [not exceeding 150 mg/(m2·d)](I) Expert consensus on the diagnosis and treatment of Alport syndrome (version 2023) (17). (II) Recommendations for the diagnosis and treatment of Alport syndrome (18)Not listed in MicromedexAS, Alport syndrome. Off-label drug usage catalog for treating pediatric AS AS, Alport syndrome. Off-label drug use for pediatric autoimmune encephalitis (AE) treatment AE represents a spectrum of neuroinflammatory disorders mediated by autoantibodies directed against neuronal cell surface or synaptic proteins, resulting in impaired neuronal function. Among the various subtypes, anti-N-methyl-D-aspartate receptor encephalitis (NMDARE) predominates, accounting for approximately 54–80% of AE cases, with leucine-rich glioma inactivated protein 1 (LGI1) antibody-associated encephalitis and gamma-aminobutyric acid B type receptor (GABABR) antibody-associated encephalitis being the subsequent most common forms (19). NMDARE predominantly manifests in pediatric and young adult populations. NMDARE exhibits an incidence rate of 0.17 cases per 100,000 individuals, with the majority of patients demonstrating a favorable clinical prognosis (20). Nevertheless, acute-phase mortality rates range between 5% and 10%, and a subset of patients may develop persistent neurocognitive and psychiatric sequelae (20). The therapeutic approach to AE is primarily immunomodulatory, structured into three distinct phases: first-line immunotherapy, second-line immunotherapy, and maintenance immunotherapy. First-line therapeutic interventions include corticosteroids (e.g., intravenous methylprednisolone), and/or intravenous immunoglobulin (IVIg), therapeutic plasma exchange (TPE) (20). For patients exhibiting inadequate clinical response (no clear improvement in function and the score on the Pediatric Modified Rankin Scale is ≥4 with no decrease) after approximately two weeks of two or more first-line therapies, second-line treatments such as rituximab, cyclophosphamide, or intravenous/intrathecal methotrexate are recommended. In cases of refractory NMDAR encephalitis, escalation to tocilizumab is advised. Maintenance immunotherapy is not routinely recommended; however, in pediatric patients with relapsed NMDAR encephalitis, IVIg may be considered as a maintenance option. Alternative agents for relapsed NMDAR encephalitis in pediatric patients include mycophenolate mofetil, azathioprine, and methotrexate, which may also be considered. It should be noted that none of these therapeutic agents have been approved for AE treatment. Table 2 presents the expert consensus on the off-label use of drugs to treat pediatric NMDARE. Table 2Off-label drug usage catalog for treating pediatric NMDAREGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageRituximabInjectionNMDAREChildrenIntravenous infusion, 750 mg/m2 (max 1 g), repeated once after 2 weeks for a total of 2 doses; alternatively, 375 mg/m2 weekly for 4 weeks(I) Practical guidelines on the diagnosis and treatment for children with N-methyl-D-aspartate receptor antibody encephalitis [2024] (20). (II) International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis (21)Not listed in MicromedexCyclophosphamideInjectionNMDARE–Intravenous infusion, 500–1,000 mg/m2 (max 1,500 mg), once a month, for a maximum duration of 6 months(I) Practical guidelines on the diagnosis and treatment for children with N-methyl-D-aspartate receptor antibody encephalitis [2024] (20). (II) International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis (21)Not listed in MicromedexMycophenolate mofetilTablet/capsule/dry suspensionNMDARE–Oral administration, 600 mg/m2 (max 1 g), twice a day(I) Practical guidelines on the diagnosis and treatment for children with N-methyl-D-aspartate receptor antibody encephalitis [2024] (20). (II) International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis (21)Not listed in MicromedexAzathioprineTabletNMDARE–Oral administration, 1–3 mg/(kg·d) (max 150 mg/d), divided into two or three individual dosesPractical guidelines on the diagnosis and treatment for children with N-methyl-D-aspartate receptor antibody encephalitis [2024] (20)Not listed in MicromedexMethotrexateTablet/injectionNMDARE–Oral administration, 10 mg/m2 once a week; or intrathecal injection, 10 mg once a weekPractical guidelines on the diagnosis and treatment for children with N-methyl-D-aspartate receptor antibody encephalitis [2024] (20)Not listed in MicromedexTocilizumabInjectionNMDARE–Intravenous infusion, for body weight <30 kg, 12 mg/kg; for body weight ≥30 kg, 8 mg/kg; maximum dose 800 mg, once monthly(I) Practical guidelines on the diagnosis and treatment for children with N-methyl-D-aspartate receptor antibody encephalitis [2024] (20). (II) International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis (21)Not listed in MicromedexNMDARE, anti-N-methyl-D-aspartate receptor encephalitis. Off-label drug usage catalog for treating pediatric NMDARE NMDARE, anti-N-methyl-D-aspartate receptor encephalitis. Off-label drug use for pediatric congenital hyperinsulinism (CHI) treatment CHI represents a heterogeneous group of genetic disorders characterized by persistent hypoglycemia resulting from dysregulated insulin secretion, distinct from acquired hyperinsulinemic conditions such as insulinoma, postprandial hyperinsulinemia, or iatrogenic insulin overdose. CHI manifests in two distinct clinical forms: a transient variant, typically resolving by 3 to 4 months of age, and a persistent form characterized by prolonged duration (22). The estimated incidence ranges from 1 in 50,000 to 1 in 30,000 live births, though comprehensive epidemiological data specific to the Chinese population remain to be established (23). Hypoglycemia can lead to irreversible severe brain damage, with the incidence of sequelae ranging from 25% to 50%, and may even result in death if not treated promptly (24). The fundamental therapeutic objective in CHI management is the maintenance of plasma glucose concentrations within appropriate physiological ranges (3.9–5.6 mmol/L) through intravenous glucose administration, thereby mitigating the risk of hypoglycemia-induced neurological sequelae (25). Diazoxide is a potassium channel agonist targeting pancreatic β-cell KATP channels, as the first-line pharmacological intervention, which has been approved for pediatric CHI in China. In cases of diazoxide intolerance or resistance, alternative therapeutic modalities including octreotide, glucagon, nifedipine, lanreotide, and sirolimus have been employed with varying degrees of efficacy (26). Table 3 presents the expert consensus on the off-label use of drugs for pediatric CHI. Table 3Off-label drug usage catalog for treating pediatric CHIGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageOctreotideInjectionCHIChildrenSubcutaneous injection, initial dose 5 μg/(kg·d), every 6–8 hours, increase gradually as needed, generally the maximum is 20 μg/(kg·d)(I) Clinical practice guidelines for congenital hyperinsulinism (22). (II) Expert consensus on the diagnosis and treatment of congenital hyperinsulinemic hypoglycemia [2022] (26)Not listed in MicromedexCHI, congenital hyperinsulinism. Off-label drug usage catalog for treating pediatric CHI CHI, congenital hyperinsulinism. Off-label drug use for juvenile generalized myasthenia gravis (MG) treatment MG is a rare autoimmune disorder mediated by antibodies targeting antigenic determinants at the neuromuscular junction, predominantly the acetylcholine receptor (AChR), and less frequently, muscle-specific tyrosine kinase (MuSK) or lipoprotein-related protein 4 (LRP4). The age and sex adjusted incidence of MG was 0.68 per 100,000 person-years in China (27). A population-based study conducted in Southern China revealed that 45% of MG cases manifest during childhood (<14 years) (28). Juvenile MG, defined as the onset of MG in individuals under 18 years of age, is predominantly characterized by ocular involvement and rarely progresses to generalized MG. Acetylcholinesterase inhibitors, particularly pyridostigmine bromide, is recommended as first-line therapy for all subtypes of MG, and has been approved for treatment of MG in adults in China (29). Immunotherapy is applicable to patients who have failed to achieve therapeutic goals despite optimal symptom management, including intravenous IVIg, glucocorticoids, immunosuppressants, biologics and plasma exchange (29). In China, several immunotherapeutic agents, including azathioprine, cyclophosphamide, eculizumab, ravulizumab, rozanolixizumab and efgartigimod alfa, have been approved for MG treatment. Notably, eculizumab, ravulizumab, rozanolixizumab, and efgartigimod alfa are specifically indicated for adults with generalized MG and are used off-label in pediatric patients. There are no formal guidelines for the use of immunosuppressive therapy in juvenile MG and current practice has been taken from adult guidelines and expert opinions based on individual experience (29,30). Table 4 presents the expert consensus on the off-label use of drugs for juvenile generalized MG. Table 4Off-label drug usage catalog for treating juvenile generalized MGGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosagePyridostigmine bromideTabletGeneralized MGChildrenOral administration, Neonates: initial 1–1.5 mg/(kg·d), gradually increased with a max daily dose of 10 mg in divided doses; 1 month–12 years: initial 1–1.5 mg/(kg·d), increase up to 7 mg/(kg·d) taken in 4–6 divided doses, with a common range of 30–360 mg/d; 12–18 years: 30–120 mg per time, with daily divided doses based on condition and a total daily amount up to 300–600 mg(I) MHRA approved (Product Information: Pyridostigmine bromide tablets, Flynn Pharma Ltd., 2024) (31). (II) Chinese National Formulary · Chemicals and Biological Products for Children (32). (III) Guideline for the management of myasthenic syndromes (30)Effectiveness Class IIb, Recommendation Class IIb, Evidence Category CTacrolimusCapsule/granulesGeneralized MG–Administer orally at a dosage of 0.05–0.10 mg/(kg·d), maintaining trough concentration at 2–9 ng/mL(I) Guideline for the management of myasthenic syndromes (30). (II) Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 version) (29)Not listed in MicromedexMycophenolate mofetilTablet/capsule/suspensionGeneralized MG–Administer orally at 600 mg/m2 (max 1 g), twice daily(I) Guideline for the management of myasthenic syndromes (30). (II) Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 version) (29)Not listed in MicromedexRituximabInjectionGeneralized MGChildrenIntravenous infusion, there is currently no unified standard for the treatment regimen. A common one is 375 mg/m2, once weekly for 4 weeks. Subsequently, the second course of treatment will be initiated according to the patient’s condition(I) Guideline for the management of myasthenic syndromes (30). (II) Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 version) (29). (III) Rituximab in juvenile myasthenia gravis-an international cohort study and literature review (33)Not listed in MicromedexEculizumabInjection–Children ≥6 years (generalized MG with positive anti-acetylcholine receptor antibodies)Intravenous infusion, based upon body weight, according to the following schedule: 5 kg to less than 10 kg, 300 mg single dose at week 1, 300 mg at week 2, then 300 mg every 3 weeks; 10 kg to less than 20 kg, 600 mg single dose at week 1, 300 mg at week 2, then 300 mg every 2 weeks; 20 kg to less than 30 kg, 600 mg for the first 2 weeks, 600 mg at week 3, then 600 mg every 2 weeks; 30 kg to less than 40 kg, 600 mg for the first 2 weeks, 900 mg at week 3, then 900 mg every 2 weeks; 40 kg and over, 900 mg weekly for the first 4 weeks, 1,200 mg at week 5, then 1,200 mg every 2 weeksFDA approved (Product Information: Eculizumab injection, Alexion Pharmaceuticals Inc., 2025) (34)Not listed in MicromedexFDA, Food and Drug Administration; MG, myasthenia gravis; MHRA, Medicines and Healthcare products Regulatory Agency. Off-label drug usage catalog for treating juvenile generalized MG FDA, Food and Drug Administration; MG, myasthenia gravis; MHRA, Medicines and Healthcare products Regulatory Agency. Off-label drug use for pediatric Wilson disease (WD) treatment WD, also referred to as hepatolenticular degeneration, is an autosomal recessive disorder of copper metabolism resulting from mutations in the ATPase copper transporting beta (ATP7B) gene, which leads to pathological copper accumulation primarily in the liver and brain, as well as other organs (35). Epidemiological data from Germany and Japan report WD prevalence rates of 29 and 33 cases per 1,000,000 individuals, respectively, while studies in China indicate a higher prevalence of 58.7 cases per 1,000,000 (36-38). Although WD can present at any age, it is most frequently diagnosed in pediatric and adolescent populations (39). Management of WD requires lifelong intervention, with therapeutic strategies encompassing pharmacological agents and, in severe cases, liver transplantation. Pharmacological treatments are classified into two main categories: copper chelators and intestinal copper absorption inhibitors (40). These agents function through distinct mechanisms but share the common therapeutic goal of reducing systemic copper accumulation and maintaining a negative copper balance. In China, D-penicillamine, dimercaptosuccinic acid, and trientine have been approved for WD treatment. Current clinical guidelines recommend initial treatment for symptomatic patients with WD should include a chelating agent (D-penicillamine or trientine), while zinc or chelators may be used for either asymptomatic patients without signs of significant liver involvement or those in maintenance therapy (40-42). Table 5 presents the expert consensus on the off-label use of drugs for pediatric WD. Table 5Off-label drug usage catalog for treating pediatric WDGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulation Specific usage and dosageZinc gluconateTablet/capsule/oral solution/granuleWD–Oral administration, the dosage is calculated based on elemental zinc. For adults and older children, the dosage is 150–220 mg/d, taken in three divided doses. For children aged 5 to 15 years and those weighing less than 50 kg, the dosage is 75 mg/d, taken in three divided doses. For children under 5 years old, the dosage is 50 mg/d, taken in two divided doses(I) Guidelines for the diagnosis and treatment of hepatolenticular degeneration (2022 edition) (40). (II) A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases (41). (III) EASL-ERN Clinical Practice Guidelines on Wilson’s disease (42)Not listed in MicromedexWD, Wilson disease. Off-label drug usage catalog for treating pediatric WD WD, Wilson disease. Off-label drug use for pediatric hyperphenylalaninemia (HPA) treatment HPA represents a group of prevalent amino acid metabolism disorders primarily attributed to deficiencies in phenylalanine hydroxylase (PAH) or its essential coenzyme, tetrahydrobiopterin (BH4), leading to elevated blood phenylalanine (Phe) levels. Etiologically, HPA is classified into two major categories: PAH deficiency and BH4 deficiency, both inherited as autosomal recessive traits. Epidemiological analysis of neonatal screening data from 35 million births in China [1985–2011] identified an HPA prevalence of 1:10,397 (43). Clinically, management strategies focus on maintaining Phe concentrations within target ranges through Phe-restricted dietary regimens, often combined with pharmacological interventions (43). For PAH deficiency, a Phe-restricted diet remains the cornerstone of treatment, while adjunctive therapy with BH4 (sapropterin) may benefit patients with suboptimal Phe control due to dietary noncompliance. In cases of BH4 deficiency, sapropterin is the primary therapeutic option for patients with GTP cyclohydrolase I deficiency (GTPCHD), 6-pyruvoyltetrahydropterin synthase (PTPS) deficiency, and pterin-4α-carbinolamine dehydratase (PC) deficiency. Additionally, most patients with PTPS deficiency and dihydropteridine reductase (DHPR) deficiency require combination therapy with L-Dopa/decarboxylase inhibitors and 5-hydroxytryptophan. Table 6 presents the expert consensus on the off-label use of drugs for pediatric HPA. Table 6Off-label drug usage catalog for treating pediatric HPAGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageSapropterinTablet–Children ≤4 years [HPA with tetrahydrobiopterin (BH4) deficiency that responds to treatment with sapropterin]Take orally at a dosage of 1–5 mg/(kg·d) in two divided doses(I) MHRA approved (Product Information: Sapropterin dihydrochloride tablets, Amarox Limited, 2025) (44). (II) Guidelines for Diagnosis and Treatment of Rare Diseases (2019 Edition) (43)Not listed in MicromedexLevodopa and benserazideTablet/capsule/spansuleHPA caused by deficiency PTPS and DHPRChildrenAdminister orally. Calculated based on the dose of levodopa, the initial dose is 0.5–1 mg/(kg·d), to be taken 2–6 times a day; the principle of slow increment should be followed. It is recommended to increase by 0.5–1 mg/(kg·d) every week until the target dose of 10 mg/(kg·d) is reached or the maximum tolerated dose of the patient is achieved(I) Guidelines for Diagnosis and Treatment of Rare Diseases (2019 Edition) (43). (II) Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies (45)Not listed in MicromedexCarbidopa/levodopaControlled release tablet/Sustained release tabletsHPA caused by deficiency PTPS and DHPRChildrenAdminister orally. Calculated based on the dose of levodopa, the initial dose is 0.5–1 mg/(kg·d), to be taken 2–6 times a day; the principle of slow increment should be followed. It is recommended to increase by 0.5–1 mg/(kg·d) every week until the target dose of 10 mg/(kg·d) is reached or the maximum tolerated dose of the patient is achieved(I) Guidelines for Diagnosis and Treatment of Rare Diseases (2019 Edition) (43). (II) Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies (45)Not listed in MicromedexDHPR, dihydropteridine reductase; HPA, hyperphenylalaninemia; MHRA, Medicines and Healthcare products Regulatory Agency; PTPS, 6-pyruvoyltetrahydropterin synthase. Off-label drug usage catalog for treating pediatric HPA DHPR, dihydropteridine reductase; HPA, hyperphenylalaninemia; MHRA, Medicines and Healthcare products Regulatory Agency; PTPS, 6-pyruvoyltetrahydropterin synthase. Off-label drug use for pediatric idiopathic pulmonary arterial hypertension (PAH) treatment PAH represents a multifactorial vascular disorder characterized by increased pulmonary vascular resistance resulting from vasoconstriction and structural remodeling of the pulmonary vasculature. Epidemiological data indicate that the annual incidence of pediatric PAH in Europe ranges from 4 to 10 cases per million, with a prevalence of 24–40 cases per million, while in the United States, the annual incidence is 5–8 cases per million, with a prevalence of 26–33 cases per million (46-48). The WHO has classified pulmonary hypertension into five distinct groups based on clinical and pathophysiological characteristics (49). Idiopathic PAH (IPAH), a rare but highly heritable and fatal condition, is defined as pre-capillary PAH of unknown etiology and constitutes up to 70% of all PAH cases (50). In a national multicenter prospective registry (China, 2009–2019), 247 children aged 3 months to 18 years with PAH were analyzed; 37.7% had IPAH or heritable PAH (HPAH), while 61.5% had PAH associated with congenital heart disease (CHD) (51). In another study of 170 Chinese children with IPAH/HPAH at a tertiary center, genetic testing identified pathogenic variants in ~64% of them (mainly in BMPR2, ACVRL1, TBX4). The 1-, 3-, and 5-year survival rates in that cohort were 93.4%, 86.7%, and 68.6%, respectively. Patients with pathogenic variants had significantly worse outcomes (52). IPAH patients exhibit significantly worse survival outcomes compared to those with PAH associated with CHD (50). Current therapeutic strategies focus on three key pathogenic pathways in PAH: prostacyclin analogs, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Data demonstrate improved survival rates with the use of these targeted therapies (53). In China, several targeted drugs, including bosentan, ambrisentan, macitentan, sildenafil, riociguat, treprostinil, and selexipag have been approved for PAH treatment. Notably, bosentan is the only agent approved for pediatric use (≥3 years), while the remaining therapies are exclusively approved for adult patients. Table 7 presents the expert consensus on the off-label use of drugs for pediatric IPAH. Table 7Off-label drug usage catalog for treating pediatric IPAHGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageSildenafilTablet/disintegrating tablet–Children (IPAH)Oral administration, for age <1 year, 0.5–1 mg/kg, three times daily; for body weight ≤20 kg, 10 mg, three times daily; for body weight >20 kg, 20 mg, three times daily(I) MHRA approved (Product Information: Sildenafil oral suspension, Rosemont Pharmaceuticals Ltd, 2024) (54). (II) Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Arterial Hypertension (2021 Edition) (55)Pulmonary hypertension, WHO function level I: Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BTadalafilTabletIPAHChildren ≥2 years Oral administration, for body weight ≥40 kg, 40 mg/d; for body weight <40 kg, 20 mg/dMHRA approved (Product Information: Tadalafil film-coated tablets, Eli Lilly and Company Limited, 2023) (56)Not listed in MicromedexTreprostinilInjection–Children (IPAH)Continuous subcutaneous or intravenous infusion, starting dose: 2 ng/kg/min without a known maximum. In children, a stable dose is usually 50–100 ng/kg/min. Dose increases may be required(I) 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (57). (II) Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Arterial Hypertension (2021 Edition) (55)Not listed in MicromedexIPAH, idiopathic pulmonary arterial hypertension; MHRA, Medicines and Healthcare products Regulatory Agency; WHO, World Health Organization. Off-label drug usage catalog for treating pediatric IPAH IPAH, idiopathic pulmonary arterial hypertension; MHRA, Medicines and Healthcare products Regulatory Agency; WHO, World Health Organization. Off-label drug use for pediatric Langerhans cell histiocytosis (LCH) treatment LCH is a rare hematological disorder characterized by local or generalized, uncontrolled proliferation and infiltration of Langerhans type of histiocytic cells (58). As the most prevalent histiocytic disorder, the annual incidence of LCH has been reported at 2.6–8.9 cases per million children, more prevalent in children than adults (59). Although clinical outcomes have improved significantly in recent decades, the progression-free survival rate for high-risk patients remains suboptimal, consistently below 50% (58). Therapeutic approaches are stratified according to disease extent and severity at presentation, with current standard treatments primarily involving corticosteroids and cytostatic agents, particularly vinca alkaloids (60). For patients with suboptimal response to first-line therapy, salvage regimens using high-dose nucleoside analogs (e.g., cladribine or cytarabine) may be effective but are associated with substantial toxicity (60). Notably, emerging therapeutic strategies, including mitogen-activated protein kinase (MAPK) inhibitors, have shown promise in managing severe and refractory cases (61). However, it is important to highlight that no pharmacological agents have yet received regulatory approval for LCH treatment in China. Table 8 presents the expert consensus on the off-label use of drugs for pediatric LCH. Table 8Off-label drug usage catalog for treating pediatric LCHGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageVindesineInjectionLCH–Intravenous injection or infusion, induction therapy 1 (weeks 1–6): 3 mg/m2 (for those weighing <10 kg, 0.1 mg/kg) (max 4 mg), once weekly for 6 weeks. If condition improves, enter maintenance directly. Induction therapy 2 (weeks 7–12): same regimen as induction 1. Maintenance Therapy: once every 3 weeks until the total treatment course reaches 1 year (half year for some single system cases)Guidelines for the Diagnosis and Treatment of Langerhans Cell Histiocytosis in Children (2021 Edition) (60)Not listed in MicromedexVincristineInjectionLCH–Intravenous injection or infusion, induction 1 (weeks 1–6): 1.5 mg/m2 (max 2 mg), once weekly for 6 weeks. If condition improves, enter maintenance directly. Induction 2 (weeks 7–12): same regimen as induction 1. Maintenance: once every 3 weeks until the total treatment course reaches 1 year (half year for some single system cases)Guidelines for the Diagnosis and Treatment of Langerhans Cell Histiocytosis in Children (2021 Edition) (60)Not listed in MicromedexPrednisoneTableLCH–Oral administration, induction 1 (weeks 1–6): 40 mg/(m2·d), after 4 weeks of full-dose use, taper off over the next 2 weeks. If condition improves, enter maintenance directly. Induction 2 (weeks 7–12): 3 days a week. Maintenance therapy: 5 days every 3 weeks until the total treatment course reaches 1 year (half year for some single system cases)(I) Guidelines for the Diagnosis and Treatment of Langerhans Cell Histiocytosis in Children (2021 Edition) (60). (II) Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents (62)Not listed in MicromedexMercaptopurineTableLCH–Oral administration, 50 mg/(m2·d), adjusted according to the patient’s toleranceGuidelines for the Diagnosis and Treatment of Langerhans Cell Histiocytosis in Children (2021 Edition) (60)Not listed in MicromedexCyclophosphamideInjectionLCH–Intravenous infusion, induction: 10 mg/(kg·d), administered on days 1–5, 15–19, and 29–33 of chemotherapy; maintenance: 10 mg/kg, administered once every 6 weeks (W4, W10, W16, W22)Exploration of treatment in childhood Langerhans cell histiocytosis based on inflammatory and malignant symptoms: a pilot study (63)Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BCladribineInjectionLCHChildrenIntravenous infusion, 9 mg/(m2·d), administered on days 2–4 of chemotherapy(I) Guidelines for the Diagnosis and Treatment of Langerhans Cell Histiocytosis in Children (2021 Edition) (60). (II) Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study (64)Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BCytarabineInjectionLCH–Intravenous infusion, 150 mg/(m2·d), given on days 1–5 of chemotherapy (I) Guidelines for the Diagnosis and Treatment of Langerhans Cell Histiocytosis in Children (2021 Edition) (60). (II) Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study (64)Not listed in MicromedexVemurafenibTableLCH (BRAFV600E mutation)ChildrenOral administration, 10 mg/kg, twice daily for at least 8 weeks. Dosage & duration depend on patient tolerance, pharmacokinetics and efficacyVemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study (61)Not listed in MicromedexLCH, Langerhans cell histiocytosis; W, week. Off-label drug usage catalog for treating pediatric LCH LCH, Langerhans cell histiocytosis; W, week. Off-label drug use for pediatric Leber hereditary optic neuropathy (LHON) treatment LHON represents a rare maternally inherited disorder characterized by painless, sequential bilateral central vision loss, primarily attributed to mitochondrial DNA (mtDNA) mutations that induce retinal ganglion cell degeneration. The disease is predominantly associated with three primary mtDNA point mutations: m.3460G>A (MTND1), m.11778G>A (MTND4), and m.14484T>C (MTND6) (65). Notably, the m.11778G>A mutation accounts for 90.2% to 92.8% of cases among Chinese patients (66). Although LHON can manifest at any age, its onset most frequently occurs between 10 and 30 years. Epidemiological studies reveal significant regional variability in LHON prevalence, with estimates of 1 in 31,000 individuals in North East England and 1 in 54,000 in Denmark (67). To date, no definitive cure exists for LHON, and clinical management mainly aims to preserve residual vision and support quality of life. Emerging therapeutic strategies under investigation include mitochondrial antioxidants, gene therapy, mitochondrial replacement, and stem cell therapy (68). Among these, idebenone, a mitochondrial antioxidant, received approval from the European Medicines Agency in June 2015 for the treatment of visual impairment in LHON patients, based on robust clinical evidence (69). In China, idebenone is not yet formally approved for LHON and is used off-label. A randomized controlled trial registered in China is currently underway, which aims to evaluate the efficacy and safety of idebenone in the treatment of LHON (ChiCTR2200059044). Table 9 presents the expert consensus on the off-label use of drugs for pediatric LHON. Table 9Off-label drug usage catalog for treating pediatric LHONGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageIdebenoneTableLHONChildren ≥12 yearsOral administration, 300 mg, three times a dayMHRA approved (Product Information: Idebenone film-coated table, Chiesi Limited, 2024) (70)Not listed in MicromedexLHON, Leber hereditary optic neuropathy; MHRA, Medicines and Healthcare products Regulatory Agency. Off-label drug usage catalog for treating pediatric LHON LHON, Leber hereditary optic neuropathy; MHRA, Medicines and Healthcare products Regulatory Agency. Off-label drug use for pediatric multiple sclerosis (MS) treatment MS is a chronic immune-mediated inflammatory disorder characterized by demyelination within the central nervous system (CNS), exhibiting both temporal and spatial dissemination of lesions. While MS predominantly affects young adults, pediatric cases are also reported, a comprehensive meta-analysis encompassing 13 epidemiological studies has estimated the global annual incidence of pediatric-onset MS to be 0.87 cases per 100,000 individuals (71). Notably, pediatric-onset MS appear to be associated with a higher relapse frequency compared to adult-onset MS (72). In the acute phase, therapeutic strategies such as corticosteroids, plasma exchange, and intravenous IVIg are recommended to mitigate symptom severity, shorten relapse duration, and limit disability progression (73). Early initiation of disease-modifying therapies (DMTs) has been shown to reduce relapse rates and slow disease progression (74). DMTs for adult MS patients are frequently utilized in pediatric MS cases. However, the evidence base remains limited, as comprehensive data from large pediatric cohorts are currently unavailable. In China, several DMTs, including teriflunomide, fingolimod, siponimod, ozanimod, dimethyl fumarate, ofatumumab, glatiramer acetate, and interferon beta have been approved for MS treatment. However, only teriflunomide and fingolimod are currently approved for pediatric use, specifically for children aged 10 years and older in China. Table 10 presents the expert consensus on the off-label use of drugs for pediatric MS. Table 10Off-label drug usage catalog for treating pediatric MSGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageDimethyl fumarateEnteric-coated capsuleMSChildren ≥13 yearsOral administration, initial dose of 120 mg, twice daily for 7 days, followed by an increase to 240 mg, twice dailyMHRA approved (Product Information: Dimethyl fumarate gastro-resistant hard capsule, Celix Pharma Ltd., 2024) (75)Not listed in MicromedexMS, multiple sclerosis; MHRA, Medicines and Healthcare products Regulatory Agency. Off-label drug usage catalog for treating pediatric MS MS, multiple sclerosis; MHRA, Medicines and Healthcare products Regulatory Agency. Off-label drug use for neonatal diabetes mellitus (NDM) treatment NDM represents a rare monogenic form of diabetes, typically presenting within the first six months of life, with a subset of cases emerging between 6 to 12 months of age. The condition occurs with an estimated prevalence of 1 in 300,000–500,000 live births (76,77). Clinically, NDM is categorized into two distinct subtypes based on disease progression: permanent NDM and transient NDM. NDM arises from diverse genetic mutations, predominantly those affecting the development and/or functionality of pancreatic beta cells, leading to critically reduced or undetectable plasma insulin levels (78). Heterozygous mutations in the KCNJ11 and ABCC8 genes, which encode the subunits of the ATP-sensitive potassium (K_ATP) channel, are implicated in approximately 50% of permanent NDM cases (79). Initial management of neonates typically involves insulin therapy, with sulfonylureas serving as a viable alternative for select patients. Notably, approximately 90% of patients with permanent NDM caused by KCNJ11 or ABCC8 mutations respond favorably to sulfonylurea treatment, which often allows discontinuation of insulin and improves glycemic control (79). A systematic review and meta-analysis including ~285 patients with K_ATP channel mutations reported a pooled success rate of ~90.1% [95% confidence interval (CI): 85.1–93.5%] when transitioning from insulin to oral sulfonylureas (80). Significant reductions in HbA1c were observed. Mild side-effects (mostly gastrointestinal) were the most common adverse events. In China, a study has shown effectiveness and safety of sulfonylurea therapy when initiated during infancy, even before genetic results are fully available (81). Glibenclamide, the most widely used sulfonylurea in this setting, is available as an oral suspension (AMGLIDIA) approved by the European Medicines Agency specifically for NDM (82). Glibenclamide is not yet approved for use in the pediatric population in China. For other forms of permanent NDM, insulin remains the sole therapeutic option. Table 11 presents the expert consensus on the off-label use of drugs for NDM. Table 11Off-label drug usage catalog for treating NDMGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageGlibenclamideCapsule/tabletNDM (KCNJ11 and ABCC8 gene mutation)ChildrenOral administration, initiated at a dose of 0.2 mg/(kg·d), divided into two doses before feeding and increased by 0.2 mg/(kg·d) until insulin independence is achieved. The average daily dose is expected to be around 0.2–0.5 mg/(kg·d) in most of the patients and a further dose increase up to 2.8 mg/(kg·d) may be tried in selected cases(I) EMA approved (Product Information: Glibenclamide oral suspension, AMMTek, 2018) (83). (II) Guidelines for Diagnosis and Treatment of Rare Diseases (2019 Edition) (43)Not listed in MicromedexEMA, European Medicines Agency; NDM, neonatal diabetes mellitus. Off-label drug usage catalog for treating NDM EMA, European Medicines Agency; NDM, neonatal diabetes mellitus. Off-label drug use for pediatric sickle cell disease (SCD) treatment SCD is a group of inherited hemoglobinopathies characterized by mutations that affect the beta-globin chain of hemoglobin, which affects approximately 100,000 people in the USA and more than 3 million people globally (84,85). SCD is characterized by a complex pathophysiology involving hemoglobin polymerization, erythrocyte sickling, chronic hemolysis, hemorheological disturbances, and subsequent multi-organ damage (86). The disease manifests clinically as chronic hemolytic anemia, recurrent vaso-occlusive crises, progressive end-organ dysfunction, and both acute and chronic pain syndromes. Hydroxyurea is the first Food and Drug Administration (FDA)-approved DMT for SCD, while recent clinical trials have led to the approval of three additional therapeutic agents: L-glutamine, voxelotor and crizanlizumab, which demonstrate efficacy in reducing acute pain episodes and ameliorating chronic anemia (L-glutamine, ClinicalTrials.gov registration number: NCT01179217; location: United States; study population age range, 5–58 years) (voxelotor, ClinicalTrials.gov registration number: NCT02850406; location: United States, Lebanon and the United Kingdom; study population age range, 4–11 years) (crizanlizumab, ClinicalTrials.gov registration number: NCT01895361; location: United States, Brazil and Jamaica; study population age range, 16–65 years) (87,88). Notably, hydroxyurea remains the only disease-modifying drug with established long-term safety and efficacy data in children, while the evidence for newer agents in pediatric populations is still limited. However, voxelotor was voluntarily withdrawn from the market by the manufacturer due to safety concerns (89). Table 12 presents the expert consensus on the off-label use of drugs for pediatric SCD. Table 12Off-label drug usage catalog for treating pediatric SCDGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageL-glutamineCapsule/granule/powderSCDChildren ≥5 yearsOral administration, twice pe day at the dose based on body weight: less than 30 kg, 10 mg/d; 30–60 mg, 20 mg/d; greater than 65 mg, 30 mg/dFDA approved (Product Information: L-glutamine oral powder, Emmaus Medical Inc., 2020) (90)Effectiveness Class I, Recommendation Class I, Evidence Category BHydroxyureaCapsule/tabletSCDChildren ≥6 monthsInitial dosing: 15 mg/kg orally once daily. Monitor the patient’s blood count every 2 weeks. The dose may be increased by 5 mg/(kg·d) every 8 to 12 weeks until a maximum tolerated dose or 35 mg/(kg·d) is reached if blood counts are in an acceptable range. The dose is not increased if blood counts are below the acceptable range and toxic. Discontinue the drug until hematologic recovery if blood counts are considered toxic. If hematologic toxicity resolved within 1 week, restart at the same dose. If hematologic toxicity persisted for more than 1 week or occurred twice in a 3-month period, reduce dose by 5 mg/(kg·d). Renal impairment: Reduce the dose by 50% in patients with creatinine clearance less than 60 mL/minFDA approved (Product Information: Hydroxyurea oral solution. Rare Disease Therapeutics Inc, 2024) (91)Effectiveness Class IIa, Recommendation Class IIa, Evidence Category BFDA, Food and Drug Administration; SCD, sickle cell disease. Off-label drug usage catalog for treating pediatric SCD FDA, Food and Drug Administration; SCD, sickle cell disease. Off-label drug use for pediatric Silver-Russell syndrome (SRS) treatment SRS is a clinically and genetically heterogeneous disorder initially described by Silver and Russell, characterized by severe intrauterine and postnatal growth retardation accompanied by diverse clinical manifestations, including hemihypertrophy, relative macrocephaly, fifth finger clinodactyly, and triangular facies (92,93). The global incidence of SRS is estimated to range between 1:30,000 and 1:100,000 (94). In ~60% of clinically diagnosed SRS patients, an (epi)genetic cause is identified (95). SRS is molecularly heterogenous, the most prevalent molecular mechanisms involve loss of methylation at chromosome 11p15 and maternal uniparental disomy for chromosome 7 (94). SRS manifests as a broad spectrum of physical and functional abnormalities, necessitating a multidisciplinary approach with early and targeted interventions to optimize patient management. Recombinant human growth hormone (rhGH) therapy has demonstrated efficacy in improving body composition, psychomotor development, and appetite in SRS patients, while also reducing the risk of hypoglycemia and enhancing growth velocity (43). Notably, the incidence of adverse effects associated with rhGH therapy is not significantly higher in children diagnosed with SRS compared to those with non-syndromic small for gestational age (94). rhGH treatment is typically initiated following the correction of nutritional deficiencies, with most patients commencing therapy between the ages of 2 to 4 years. Table 13 presents the expert consensus on the off-label use of drugs for pediatric SRS. Table 13Off-label drug usage catalog for treating pediatric SRSGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosagerhGHInjectionSRS–Administered subcutaneously. The initial dose is approximately 35 μg/(kg·d), and the minimum dose for catch-up growth is used, which typically ranges from 35 to 70 μg/(kg·d)(I) Guidelines for Diagnosis and Treatment of Rare Diseases (2019 Edition) (43). (II) Diagnosis and management of Silver-Russell syndrome: first international consensus statement (94)Not listed in MicromedexrhGH, recombinant human growth hormone; SRS, Silver-Russell syndrome. Off-label drug usage catalog for treating pediatric SRS rhGH, recombinant human growth hormone; SRS, Silver-Russell syndrome. Off-label drug use for pediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treatment AAV is a cluster of systemic disorders characterized by necrotizing inflammation of small vessels, accompanied by the presence of circulating ANCA. This disease spectrum comprises three principal subtypes: microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) (96). AAV predominantly targets small- to medium-sized vessels, resulting in multisystem involvement with a particular predilection for the respiratory tract and renal system. The incidence of AAV exhibits significant variation across different ethnic groups and geographic regions, with global prevalence estimates ranging from 48 to 184 cases per million individuals (97,98). In China, a retrospective analysis utilizing a comprehensive national inpatient database identified a prevalence of 0.25 cases per 1,000 inpatients (99). The estimated prevalence of pediatric AAV is 3.41–4.28 (95% CI: 2.33–6.19) per million children (100). The central pathogenic mechanism involves ANCA-mediated neutrophil activation, which drives disease progression through the formation of neutrophil extracellular traps, activation of the complement cascade, and modulation of the adaptive immune response (101). Immunosuppressive therapy has significantly improved clinical outcomes in AAV patients (102). The therapeutic approach is generally divided into induction therapy (aimed at achieving remission) and maintenance therapy (to prevent relapses) (103). High-quality randomized controlled trials in children with AAV are lacking; therefore, treatment protocols are mainly extrapolated from adult data and expert consensus. For newly diagnosed or relapsing AAV with organ-threatening or life-threatening manifestations, the recommended initial treatment involves glucocorticoids combined with cyclophosphamide or rituximab (103). In cases of non-severe disease, glucocorticoids in combination with mycophenolate, methotrexate, or azathioprine are recommended (103). Table 14 presents the expert consensus on the off-label use of drugs for pediatric AAV. Table 14Off-label drug usage catalog for treating pediatric AAVGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageRituximabInjectionAAVChildren ≥2 yearsThe induction dose is 375 mg/m2 once weekly for 4 weeks. The follow up is two 250 mg/m2 intravenous infusions separated by two weeks, followed by a 250 mg/m2 intravenous infusion every 6 months thereafter based on clinical evaluation(I) FDA approved (Product Information: Rituximab injection, Genentech, Inc., 2021) (104). (II) KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (102)GPA: Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BCyclophosphamideTablet/injectionAAV–(I) Oral administration, at a dosage of 2 mg/(kg·d), continuously for 3 months, with the maximum treatment duration not exceeding 6 months. (II) Intravenous infusion, at a dosage of 15 mg/kg (max 1.2 g), administered every 2 weeks for the first 3 times, then every 3 weeks thereafter; or at a dosage of 750 mg/m2, administered every 4 weeks, for a total of 4 to 7 times. The treatment duration is 3 to 6 months, until the disease remains inactive(I) KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (102). (II) Consensus on diagnosis and treatment of childhood vasculitis in China: ANCA-associated vasculitis (103)Not listed in MicromedexAzathioprineTabletAAV–Oral administration, initial dose of 1.5–2 mg/(kg·d), after 12 months, reduce by 25 mg every 3 months; or initial dose of 1.5–2 mg/(kg·d), after 18–24 months, reduce to 1 mg/(kg·d), and after 48 months, reduce by 25 mg every 3 months(I) KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (102). (II) Consensus on diagnosis and treatment of childhood vasculitis in China: ANCA-associated vasculitis (103)Not listed in MicromedexMethotrexateTablet/injectionAAV–Administer orally, subcutaneously or intramuscularly at a dose of 0.5–0.7 mg/kg (max 25 mg), once a week(I) KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (102). (II) Consensus on diagnosis and treatment of childhood vasculitis in China: ANCA-associated vasculitis (103)Not listed in MicromedexMycophenolate mofetilTablet/dispersive tablet/capsuleAAV–Orally administered at a dose of 20–30 mg/(kg·d) (max 2 g/d)(I) KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (102). (II) Consensus on diagnosis and treatment of childhood vasculitis in China: ANCA-associated vasculitis (103)Not listed in MicromedexANCA, anti-neutrophil cytoplasmic antibody; AAV, ANCA-associated vasculitis; FDA, Food and Drug Administration; GPA, granulomatosis with polyangiitis; KDIGO, Kidney Disease: Improving Global Outcomes. Off-label drug usage catalog for treating pediatric AAV ANCA, anti-neutrophil cytoplasmic antibody; AAV, ANCA-associated vasculitis; FDA, Food and Drug Administration; GPA, granulomatosis with polyangiitis; KDIGO, Kidney Disease: Improving Global Outcomes. Off-label drug use for pediatric biliary atresia (BA) treatment BA represents a severe and life-threatening neonatal disorder characterized by progressive inflammation and fibrosis, leading to partial or complete obliteration of both intrahepatic and extrahepatic bile ducts. Without timely intervention, BA invariably progresses to end-stage liver disease, making it the most common indication for pediatric liver transplantation (105). The incidence of BA exhibits significant geographical and ethnic variation, with reported rates of 1 in 5,000–10,000 live births in China and Japan, compared to 1 in 15,000–20,000 in Europe and North America (106-110). The Kasai portoenterostomy remains the cornerstone of surgical management for BA, significantly improving patient survival and clinical outcomes (105). Postoperative adjuvant therapies are employed to mitigate complications, with glucocorticoids frequently administered to reduce biliary tract edema and inflammation, though current high-quality randomized evidence does not support their efficacy in improving native liver survival or long-term jaundice clearance (111,112). Additionally, ursodeoxycholic acid is routinely utilized for its role in enhancement of bile excretion (111,112). Table 15 presents the expert consensus on the off-label use of drugs for pediatric BA. Table 15Off-label drug usage catalog for treating pediatric BAGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageUrsodeoxycholic acidTablet/capsuleBA–Oral administration, 10–30 mg/(kg·d), twice daily. Initiate upon postoperative feeding, with a treatment duration of 6–24 months(I) Guidelines for diagnosing & treating biliary atresia (2018 Edition) (111). (II) Clinical practice guidelines for biliary atresia in Japan: A secondary publication of the abbreviated version translated into English (112)Not listed in MicromedexPrednisoloneTabletBA–The optional regimens are as follows (but not limited to): (I) administer orally at a dose of 4 mg/(kg·d). Start taking it in the morning after the intestinal function recovers postoperatively, once a day. Take it for 4 weeks, then reduce the dose to 2 mg/(kg·d) and take it for another 4 weeks. Subsequently, reduce the dose to 1 mg/(kg·d), and stop taking it after 4 weeks of administration. (II) Intravenous infusion of methylprednisolone with doses of 10, 8, 6, 5, 4, 3, and 2 mg/(kg·d) successively for a total of 7 days. Then, sequentially administer prednisolone orally at a dose of 2 mg/(kg·d) for 4 weeks. After that, reduce the dose to 1 mg/(kg·d), and stop taking it after 4 weeks of administrationGuidelines for diagnosing & treating biliary atresia (2018 Edition) (111)Not listed in MicromedexMethylprednisoloneTablet /injectionBA–(I) Intravenous infusion at doses of 10, 8, 6, 5, 4, 3, 2 mg/(kg·d) successively for a total of 7 days, followed by oral prednisolone at 2 mg/(kg·d) for 4 weeks, then reduced to 1 mg/(kg·d) and stopped after 4 weeks. (II) Intravenous infusion 5 to 7 days after the operation at a dose of 4 mg/kg. Reduce the dose every 3 days, with a reduction of 1 mg/kg. If the jaundice does not subside well, another pulse therapy can be repeated. Then, reduce the dose to 2 mg/kg and maintain it for 12 weeks before gradually tapering off the dose. (III) Oral administration at 4 mg/(kg·d) divided in two separate doses, starting 7 days post-operation. Halve the dose after 2 weeks, maintain it at 1 mg/(kg·d) for 2 weeks, and finally stop taking it(I) Guidelines for diagnosing & treating biliary atresia (2018 Edition) (111). (II) Expert Consensus on the Diagnosis and Treatment of Biliary Atresia in Mainland China (113)Not listed in MicromedexBA, biliary atresia. Off-label drug usage catalog for treating pediatric BA BA, biliary atresia. Off-label drug use for pediatric neuroblastoma (NB) treatment NB represents one of the most prevalent extracranial solid malignancies in pediatric populations, constituting approximately 8–10% of all childhood cancers and contributing to nearly 15% of cancer-related mortality in children (114,115). The incidence of NB stands at 10.2 cases per million children under the age of 15 years, making it the most frequently diagnosed cancer during the first year of life (116). This malignancy is characterized by significant biological and clinical heterogeneity, ranging from localized tumors capable of spontaneous regression to aggressive, widely disseminated disease. The International Neuroblastoma Risk Group (INRG) has established a comprehensive classification system that integrates genetic, clinical, and pathological markers to categorize NB into four distinct risk groups: very low risk, low risk, intermediate risk, and high risk (117). Current therapeutic strategies are tailored to patient age and disease stage, encompassing modalities such as surgical resection, chemotherapy, stem cell transplantation, radiation therapy, immunotherapy, isotretinoin and eflornithine (118). Emerging targeted agents such as anaplastic lymphoma kinase (ALK) inhibitors (e.g., lorlatinib), bromodomain and extra-terminal domain (BET) inhibitors, mitogen-activated protein kinase inhibitors (e.g., binimetinib) and histone deacetylase (HDAC) inhibitors have shown promising activity in early-phase clinical trials for relapsed/refractory NB (119). Table 16 presents the expert consensus on the off-label use of drugs for pediatric NB. Table 16Off-label drug usage catalog for treating pediatric NBGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageCarboplatinInjectionNBChildrenIntravenous infusion. In the COG protocol: 560 mg/(m2·d) [body weight ≤12 kg, 18.6 mg/(kg·d)], administrated on the 1st day of chemotherapy. In the SIOPEN protocol: 200 mg/(m2·d) or 6.6 mg/(kg·d), administrated on the 1st to 3rd days of chemotherapy. For hematopoietic stem cell transplantation of high-risk NB: calculate the dosage according to age, body surface area, and glomerular filtration rate, administrated on the 7th to 4th days before the hematopoietic stem cell infusion [specific usage and dosage can be found at (120)](I) Standardized Guidelines for the Diagnosis and Treatment of Pediatric Neuroblastoma (121). (II) China Guidelines for the Integrated Diagnosis and Treatment of Cancer (CACA): Neuroblastoma (122). (III) Neuroblastoma, Version 2. 2024, NCCN Clinical Practice Guidelines in Oncology (118)Not listed in MicromedexIsotretinoinCapsuleMedium and high-risk NBChildrenAdminister orally at a dosage of 160 mg/(kg·d) for 14 consecutive days per month, with a total treatment duration of 6 months(I) Standardized Guidelines for the Diagnosis and Treatment of Pediatric Neuroblastoma (121). (II) China Guidelines for the Integrated Diagnosis and Treatment of Cancer (CACA): Neuroblastoma (122). (III) Neuroblastoma, Version 2. 2024, NCCN Clinical Practice Guidelines in Oncology (118)Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BTopotecanInjectionHigh-risk NBChildrenIntravenous infusion, 1.2 mg/(m2·d), administered on days 1 to 5 of chemotherapy(I) China Guidelines for the Integrated Diagnosis and Treatment of Cancer (CACA): Neuroblastoma (122). (II) Neuroblastoma, Version 2. 2024, NCCN Clinical Practice Guidelines in Oncology (118)Not listed in MicromedexIrinotecanInjectionHigh-risk NBChildrenIntravenous infusion, 120 mg/(m2·d), administered on days 1 to 3 of chemotherapy; or 50 mg/(m2·d), administered on days 1 to 5 of chemotherapy(I) China Guidelines for the Integrated Diagnosis and Treatment of Cancer (CACA): Neuroblastoma (122). (II) Neuroblastoma, Version 2. 2024, NCCN Clinical Practice Guidelines in Oncology (118)Not listed in MicromedexTemozolomideCapsuleHigh-risk, recurrent and/or refractory NBChildrenOral administration, 100 mg/(m2·d), administered on days 1 to 5 of chemotherapy(I) Neuroblastoma, Version 2. 2024, NCCN Clinical Practice Guidelines in Oncology (118). (II) Expert consensus on diagnosing and treating of neuroblastoma in children: CCCG-NB-2021 Regimen (123) Not listed in MicromedexThiotepaInjectionHigh-dose chemotherapy with autologous stem cell rescue for NB–Intravenous infusion for more than 2 hours, 300 mg/m2 (for patients weighing <12 kg, 10 mg/kg), once daily, administered once daily on days 7 to 5 prior to hematopoietic stem cell infusion(I) China Guidelines for the Integrated Diagnosis and Treatment of Cancer (CACA): Neuroblastoma (122). (II) Neuroblastoma, Version 2. 2024, NCCN Clinical Practice Guidelines in Oncology (118)Not listed in MicromedexMelphalanInjectionHigh-dose chemotherapy with autologous stem cell rescue for NBChildrenIntravenous infusion. (I) For single transplantation, 140 mg/m2, administered on the 3rd day before hematopoietic stem cell infusion. For tandem transplantation, 60 mg/m2 (2 mg/kg for those weighing <12 kg), once a day from the 7th to 5th day before hematopoietic stem cell infusion. (II) For single transplantation: Option 1: 70 mg/m2, once a day from the 7th to 5th day before hematopoietic stem cell infusion. Option 2: 140 mg/m2, administered on the 1st day before hematopoietic stem cell. For tandem transplantation, 60 mg/m2, once a day from the 7th to 5th day before hematopoietic stem cell infusion(I) China Guidelines for the Integrated Diagnosis and Treatment of Cancer (CACA): Neuroblastoma (122). (II) Neuroblastoma, Version 2. 2024, NCCN Clinical Practice Guidelines in Oncology (118)Not listed in MicromedexBusulfanInjectionHigh-dose chemotherapy with autologous stem cell rescue for NBChildrenIntravenous infusion, 1 mg/kg, administered every 6 hours, from the 8th to 5th day before hematopoietic stem cell infusion(I) China Guidelines for the Integrated Diagnosis and Treatment of Cancer (CACA): Neuroblastoma (122). (II) Neuroblastoma, Version 2. 2024, NCCN Clinical Practice Guidelines in Oncology (118)Not listed in MicromedexCACA, China Anti-cancer Association; CCCG-NB, Chinese Children’s Cancer Group-Neuroblastoma; COG, Children’s Oncology Group; NB, neuroblastoma; NCCN, National Comprehensive Cancer Network; SIOPEN, Societe Internationale d’Oncologie Pediatrique Europe Neuroblastoma. Off-label drug usage catalog for treating pediatric NB CACA, China Anti-cancer Association; CCCG-NB, Chinese Children’s Cancer Group-Neuroblastoma; COG, Children’s Oncology Group; NB, neuroblastoma; NCCN, National Comprehensive Cancer Network; SIOPEN, Societe Internationale d’Oncologie Pediatrique Europe Neuroblastoma. Off-label drug use for persistent pulmonary hypertension of the newborn (PPHN) treatment PPHN is marked by a failure in circulatory adaptation at birth, resulting in the continued presence of elevated pulmonary arterial pressures and reduced pulmonary blood flow during the postnatal period. This condition reflects an inadequate transition from fetal to neonatal circulation, where the pulmonary vascular resistance remains abnormally high, impeding normal blood flow dynamics after birth. This condition occurs in approximately 2 per 1,000 live births and is associated with significant mortality rates, ranging from 7% to 35.7% (124-126). The pathogenesis of PPHN is multifactorial, involving aberrant pulmonary vascular remodeling, endothelial dysfunction, and altered vascular reactivity, all of which contribute to the persistent increase in pulmonary arterial pressure. Therapeutic strategies for PPHN encompass supportive care, ventilation and oxygenation support, pulmonary vasodilator therapy, and other medications (127). Inhaled nitric oxide (iNO), a pulmonary vasodilator, is recognized as the standard of care and has been approved in China for the treatment of PPHN. However, in resource-limited settings where iNO availability is constrained, alternative medications such as sildenafil, bosentan, milrinone, and prostaglandins are utilized (127). Table 17 presents the expert consensus on the off-label use of drugs for PPHN. Table 17Off-label drug usage catalog for treating PPHNGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageBosentanTablet/dispersive tabletPPHNNewbornOral administration, 1–2 mg/kg, twice a dayExperts consensus on the management of neonatal pulmonary hypertension (128)Not listed in MicromedexSildenafilTablet/oral disintegrating tabletPPHNNewbornOral administration, 0.5–1.0 mg, administered every 6 hours(I) Pediatric Pulmonary Hypertension: Guidelines from the American Heart Association and American Thoracic Society (129). (II) Experts consensus on the management of neonatal pulmonary hypertension (128)Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BMilrinoneInjectionPPHN–Loading dose 50–75 μg/kg, administered by intravenous infusion over 30–60 minutes, then 0.50–0.75 μg/(kg·min) for maintenance. Do not use the loading dose in case of systemic hypotension. For preterm infants <30 weeks, loading dose 135 μg/kg, administered by intravenous infusion over 3 hours, then 0.2 μg/(kg·min) for maintenance(I) Pediatric Pulmonary Hypertension: Guidelines from the American Heart Association and American Thoracic Society (129). (II) Experts consensus on the management of neonatal pulmonary hypertension (128)Not listed in MicromedexPPHN, persistent pulmonary hypertension of newborn. Off-label drug usage catalog for treating PPHN PPHN, persistent pulmonary hypertension of newborn. Off-label drug use for retinopathy of prematurity (ROP) treatment ROP, a proliferative retinal vascular disorder predominantly affecting preterm infants with low birth weight, represents a major etiological factor in childhood blindness. Epidemiological studies estimate the pooled prevalence of ROP to range between 21.8–36.5% among preterm infants with a gestational age of less than 32 weeks (130). The disease severity is classified into five distinct stages (stages 1–5), with therapeutic interventions tailored according to both the stage and anatomical location of the pathology (131). The pathogenesis of ROP is multifactorial, with key contributing factors including intermittent hypoxia, oxidative stress, systemic inflammation, dysregulation of vascular endothelial growth factor (VEGF) signaling, retinal vascular immaturity, and oxygen therapy. Current therapeutic modalities primarily include laser photocoagulation and intravitreal anti-VEGF therapy, with the latter demonstrating several advantages over laser treatment, including reduced procedural duration, decreased anesthetic requirements, and minimized visual field defects (132). Long-term safety data for anti-VEGF use in ROP remain limited, particularly regarding neurodevelopmental outcomes. Clinically utilized anti-VEGF agents encompass bevacizumab, aflibercept, conbercept, and ranibizumab, with ranibizumab having received regulatory approval in China for ROP treatment. Table 18 presents the expert consensus on the off-label use of drugs for ROP. Table 18Off-label drug usage catalog for treating ROPGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageBevacizumabInjectionROPChildrenIntravitreal injection, 0.625 mg per dose(I) Expert consensus on the classification and treatment of retinopathy of prematurity in China (2023 edition) (133). (II) Efficacy of intravitreal Bevacizumab for stage 3+ retinopathy of prematurity (134)Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BAfliberceptIntraocular injection solutionROPChildrenIntravitreal injection, 0.4 mg per dose. Treatment may be given bilaterally on the same day. Injections may be repeated in each eye. The treatment interval between doses injected into the same eye should be at least 10 daysFDA approved (Product Information: Aflibercept injection for intravitreal use, Regeneron Pharmaceuticals, Inc., 2024) (135)Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BConberceptIntraocular injection solutionROPChildrenIntravitreal injection, 0.25 mg per dose(I) Expert consensus on the classification and treatment of retinopathy of prematurity in China (2023 edition) (133). (II) Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial (136)Not listed in MicromedexFDA, Food and Drug Administration; ROP, retinopathy prematurity. Off-label drug usage catalog for treating ROP FDA, Food and Drug Administration; ROP, retinopathy prematurity. Off-label drug use for systemic juvenile idiopathic arthritis (JIA) treatment JIA represents a heterogeneous group of systemic disorders of unknown etiology, characterized by the onset of chronic arthritis (persisting for ≥6 weeks) prior to 16 years of age, with exclusion of cases attributable to other known causes. As the most prevalent chronic rheumatic disease in pediatric populations, JIA demonstrates substantial epidemiological variability, with reported prevalence rates ranging from 3.8 to 400 per 100,000 children and annual incidence rates between 0.8 and 23 per 100,000 (137). Systemic JIA (sJIA), a distinct subtype, is characterized by the coexistence of systemic inflammatory features and arthritis, accounting for approximately 10–20% of all JIA cases, with an incidence rate of about 10 per 100,000 (138). Current therapeutic strategies for sJIA encompass a spectrum of pharmacological interventions, including nonsteroidal anti-inflammatory drugs, glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biologic and targeted synthetic DMARDs (139). Methotrexate, a conventional synthetic DMARD, remains the cornerstone of JIA treatment, while leflunomide serves as an alternative therapeutic option for patients exhibiting methotrexate intolerance or inadequate response. Biologic and targeted synthetic DMARDs are typically employed as second-line therapy in cases of persistent disease activity (140). Recent therapeutic advancements have focused on cytokine-targeted therapies, with particular emphasis on IL-1 inhibitors, IL-6 inhibitors, and tumor necrosis factor-α inhibitors. Registry data show increasing early use of biologic DMARDs and tapering use of conventional DMARDs, especially in severe sJIA (139). Notably, anakinra (an IL-1 receptor antagonist) and tocilizumab (a humanized anti-IL-6 receptor monoclonal antibody) have received regulatory approval for the treatment of sJIA in China. Table 19 presents the expert consensus on the off-label use of drugs for sJIA. Table 19Off-label drug usage catalog for treating sJIAGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageMethotrexateTablet/injectionsJIA–Administer orally or by subcutaneous injection at a dosage of 10–15 mg/m2 per week. Take 5 mg of folic acid the next day to counteract its adverse reactions(I) Recommendations of diagnosis and treatment of juvenile idiopathic arthritis in China (141). (II) Chinese expert consensus on diagnosis and treatment of systemic juvenile idiopathic arthritis (2023 edition) (140)Not listed in MicromedexLeflunomideTabletsJIAChildrenAdminister orally at 10 mg every other day for those weighing <20 kg, 10 mg daily for those weighing 20–40 kg, 20 mg daily for those weighing >40 kg, or at a recommended routine dose of 0.3 mg/(kg·d) for older childrenChinese expert consensus on diagnosis and treatment of systemic juvenile idiopathic arthritis (2023 edition) (140)Not listed in MicromedexCyclosporine ACapsule/oral solutionsJIA–Administer orally at a dosage of 2–3 mg/(kg·d), divided into 2 times. In cases complicated with macrophage activation syndrome, the dosage is 3–6 mg/(kg·d)(I) Recommendations of diagnosis and treatment of juvenile idiopathic arthritis in China (141). (II) Chinese expert consensus on diagnosis and treatment of systemic juvenile idiopathic arthritis (2023 edition) (140)Not listed in MicromedexThalidomideTablet/capsulesJIAChildrenAdminister orally at a dosage of 1.5–2 mg/(kg·d)(I) Recommendations of diagnosis and treatment of juvenile idiopathic arthritis in China (141). (II) 5th of the recommendations series of experts on clinical practical hot issues of children’s immune related diseases-Advice on the application of thalidomide in the immune diseases in children (142). (III) Chinese expert consensus on diagnosis and treatment of systemic juvenile idiopathic arthritis (2023 edition) (140)Not listed in MicromedexAdalimumabInjectionsJIA–Administer subcutaneously at a dose of 20 mg for those with a body weight <30 kg, and 40 mg for those with a body weight ≥30 kg, once every 2 weeks(I) Recommendations of diagnosis and treatment of juvenile idiopathic arthritis in China (141). (II) 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis (143). (III) Chinese expert consensus on diagnosis and treatment of systemic juvenile idiopathic arthritis (2023 edition) (140)Not listed in MicromedexInfliximabInjectionsJIA–Administer by intravenous infusion at a dosage of 3–5 mg/kg. Administer the 2nd dose at 2 weeks and the 3rd at 4 weeks after the 1st. Subsequent dosing intervals are based on the patient’s condition(I) Recommendations of diagnosis and treatment of juvenile idiopathic arthritis in China (141). (II) 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis (143). (III) Chinese expert consensus on diagnosis and treatment of systemic juvenile idiopathic arthritis (2023 edition) (140)Not listed in MicromedexsJIA, systemic juvenile idiopathic arthritis. Off-label drug usage catalog for treating sJIA sJIA, systemic juvenile idiopathic arthritis. Off-label drug use for pediatric Takayasu arteritis (TAK) treatment TAK represents a form of large vessel vasculitis characterized by chronic inflammation predominantly affecting the aorta and its primary branches, including the aortic arch, carotid arteries, subclavian arteries, abdominal aorta, and renal arteries. Additionally, involvement of the pulmonary and coronary arteries has been documented. A comprehensive systematic review and meta-analysis recently demonstrated an overall incidence rate of 1.11 cases per million person-years (95% CI: 0.70–1.76) (144). Epidemiological data pertaining to childhood-onset TAK remain limited. A Swedish population-based study reported an annual incidence rate of 0.4 (95% CI: 0–1.1) cases per million individuals for childhood-onset TAK (145). The precise etiological mechanisms underlying TAK remain incompletely elucidated; however, current evidence suggests a strong association with dysregulated immune-mediated processes localized within the arterial wall (146). These aberrant immunological responses are hypothesized to initiate a sequential cascade of pathophysiological alterations, characterized by endothelial cell hyperplasia, neoangiogenesis, fibrotic remodeling, and degradation of elastic laminae. Current therapeutic strategies for childhood-onset TAK are largely extrapolated from adult studies due to a paucity of high-quality evidence. Pediatric data are mostly from small case series and registries, underscoring the need for prospective trials. Standard treatment regimens include corticosteroids in combination with conventional DMARDs (e.g., cyclophosphamide, methotrexate, azathioprine, and mycophenolate mofetil) or biologic agents (e.g., TNFα and IL-6 inhibitors) to mitigate systemic and vascular inflammation (147,148). The combination of corticosteroids with DMARDs constitutes the first-line treatment for TAK. For recurrent and refractory cases, TNFα inhibitors or IL-6R inhibitors may be considered. Table 20 presents the expert consensus on the off-label use of drugs for pediatric TAK. Table 20Off-label drug usage catalog for treating pediatric TAKGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageMethotrexateTabletTAK–Administer orally at a dosage of 10–15 mg/m2 per weekConsensus on diagnosis and treatment of childhood vasculitis in China: Takayasu’s arteritis (148)Not listed in MicromedexAzathioprineTabletTAK–Administer orally at a dosage of 2 mg/(kg·d)Consensus on diagnosis and treatment of childhood vasculitis in China: Takayasu’s arteritis (148)Not listed in MicromedexInfliximabInjectionTAK–Administer by intravenous infusion at a dose of 5–6 mg/kg, once at 0, 2, 4, and 8 weeks, then once every 8 weeks; alternatively, once at 0, 2, and 4 weeks, then once every 4 weeksConsensus on diagnosis and treatment of childhood vasculitis in China: Takayasu’s arteritis (148)Not listed in MicromedexAdalimumabInjectionTAK–Administer subcutaneously at a dose of 40 mg every two weeks (body weight > 30 kg) or 24 mg/m2 (body weight ≥30 kg)Consensus on diagnosis and treatment of childhood vasculitis in China: Takayasu’s arteritis (148)Not listed in MicromedexTocilizumabInjectionTAK–Administer by intravenous infusion at a dose of 12 mg/kg for those with a body weight <30 kg or 8 mg/kg for those with a body weight ≥30 kg, once every 2–4 weeksConsensus on diagnosis and treatment of childhood vasculitis in China: Takayasu’s arteritis (148)Not listed in MicromedexTAK, Takayasu arteritis. Off-label drug usage catalog for treating pediatric TAK TAK, Takayasu arteritis. Off-label drug use for infantile epileptic spasms syndrome (IESS) treatment IESS, previously referred to as infantile spasms or West syndrome, is an age-specific epileptic disorder that manifests during early infancy, characterized by the presence of epileptic spasms hypsarrhythmia on electroencephalogram (EEG) and developmental regression. There is an incidence rate of 25–60 per 100,000 live births with a prevalence of 15–20 per 100,000 children under the age of 10 years (149). The primary therapeutic objectives for IESS are the cessation of epileptic spasms and the resolution of hypsarrhythmia on EEG. First-line treatments include adrenocorticotropic hormone (ACTH) and oral corticosteroids (150). Vigabatrin, a gamma-aminobutyric acid (GABA) transaminase inhibitor, has demonstrated efficacy in IESS cases associated with tuberous sclerosis complex (151). While evidence for their efficacy remains limited, several antiepileptic drugs, including valproic acid, benzodiazepines, topiramate, and lamotrigine, are also recommended in the management of IESS (152). In China, specific antiepileptic agents such as vigabatrin, valproic acid, and clonazepam have been approved for the treatment of IESS. Early initiation (within 4 weeks of onset) significantly improves developmental outcomes (153). Table 21 presents the expert consensus on the off-label use of drugs for IESS. Table 21Off-label drug usage catalog for treating IESSGeneric nameDosage formOff-label contentEvidence base and referencesEvidence levelIndicationPopulationSpecific usage and dosageACTHInjectionIESSChildren <2 yearsAdministered intramuscularly at a dose of 150 U/m2 divided into twice daily injections of 75 U/m2. After 2 weeks of treatment, dosing should be gradually tapered and discontinued over a 2-week period(I) FDA approved (Product Information: Acthar Gel for intramuscular or subcutaneous use, Mallinckrodt ARD LLC, 2024) (154). (II) Clinical guidelines: epilepsy volume (2023 Revised Edition) (152)Effectiveness Class IIa, Recommendation Class IIa, Evidence Category BPrednisoloneTabletIESS–Administer orally at a dosage of 10 mg, four times a day for 2 consecutive weeks. If the spasms continue after one week of treatment, increase the dosage to 20 mg, three times a day. After two weeks of treatment, reduce the dosage by 10 mg every 5 days. In case a higher dosage was previously taken, start with 40 mg per day, then 20 mg per day, and finally 10 mg per day, each for a duration of 5 days(I) Epilepsies in children, young people and adults (NG217) (155). (II) Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics (156). (III) The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial (157)Effectiveness Class IIa, Recommendation Class IIb, Evidence Category BACTH, adrenocorticotropic hormone; IESS, infantile epileptic spasms syndrome; FDA, Food and Drug Administration. Off-label drug usage catalog for treating IESS ACTH, adrenocorticotropic hormone; IESS, infantile epileptic spasms syndrome; FDA, Food and Drug Administration. Conclusions This expert consensus was formulated by synthesizing available evidence and integrating key information on clinical practices, evidence levels, and medication safety. The final version was ratified following several rounds of rigorous, iterative expert discussions. This consensus provides evidence support for the treatment of pediatric rare diseases and the management of off-label drug use. It will play a positive role in standardizing the management of such off-label use for pediatric rare diseases, enhancing pharmaceutical care for special populations, and improving the effectiveness and safety of pharmacotherapy. However, this consensus has the following limitations. First, this consensus lacks explicit classification or definitions for levels of evidence and grades of recommendation. Additionally, due to the limitations of available pediatric data, the high-quality evidence we included is relatively scarce. Subsequently, we will update our consensus on a regular basis in light of new evidence. It is important to emphasize that off-label drug use should be avoided when on-label use can yield favorable clinical outcomes. In cases where off-label drug use is deemed necessary, physicians must conduct a comprehensive evaluation of the potential benefits and risks, and adhere to the off-label drug use management protocols of medical institutions. Adverse drug reaction should be monitored and evaluated in patients who received drugs off-label. Supplementary The article’s supplementary files as Available at https://tp.amegroups.com/article/view/10.21037/tp-2025-521/prf